IMPACT BIOMEDICAL INC.

Stock Snapshot

{{stockQuote.companyFullName}}

{{stockQuote.valueFormatted}}

{{getFormattedValue(stockQuote.changesValueFormatted)}} ({{getFormattedValue(stockQuote.changesPercentFormatted)}}%)

{{stockQuote.onlyDateFormatted}} (At Close)

Previous Close

Volume

Today’s Open

Average Volume (10 days)

Day's Range

{{todayDetailedInformation.todaysLow}} - {{todayDetailedInformation.todaysHigh}}

Market Cap

52 Week Range

{{detailQuote.weekLow}} -{{detailQuote.weekHigh}}

Total Shares Outstanding

More Info

Shareholder Message

In response to many questions regarding the Impact BioMedical common stock, we provide this information regarding the stock’s possible applicable restrictions. If you hold shares that were the result of a dividend from DSS, Inc, such shares are subject to certain trading restrictions. As noted in Impact BioMedical’s Form S-1 filing of August 1, 2023, describing and notifying the dividend, it provides:

Impact BioMedical successfully launched and closed its IPO on September 13, 2024. For those investors holding shares received as a part of DSS’s dividend, the trading restriction would then end on Monday, March 13, 2025.

If you have any further questions as to the terms and restrictions of the DSS dividend of Impact stock, please refer to the following link, which can also be accessed through Impact BioMedical’s website.

Latest Company Reports

View All SEC Filings

Latest Press Releases

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

View Press Release View All News

Company Profile

Impact Biomedical drives mission-oriented discovery and development to pursue new products and treatment options in specialty biopharmaceuticals and consumer healthcare.

Our biopharmaceutical technologies have potential to advance treatment in oncology, neurology, and immunology. Consumer efforts include naturally based sugar alternatives, fragrances and insect repellents, as well antibacterial, antiviral, and antimicrobial technologies. A true spirit and desire of continuous improvement in healthcare result in continuous discovery of new technologies.

Sector

Industry